Savvy Advisors Inc. Boosts Stock Position in AbbVie Inc. (NYSE:ABBV)

Savvy Advisors Inc. boosted its position in AbbVie Inc. (NYSE:ABBV - Free Report) by 14.1% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 20,236 shares of the company's stock after purchasing an additional 2,508 shares during the quarter. Savvy Advisors Inc.'s holdings in AbbVie were worth $4,240,000 as of its most recent filing with the Securities and Exchange Commission.

• AbbVie Stock Eyes Breakout as Pipeline and Profits Grow

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Brighton Jones LLC grew its stake in AbbVie by 17.4% during the fourth quarter. Brighton Jones LLC now owns 22,912 shares of the company's stock worth $4,072,000 after buying an additional 3,401 shares during the period. Revolve Wealth Partners LLC boosted its holdings in AbbVie by 72.7% in the 4th quarter. Revolve Wealth Partners LLC now owns 7,279 shares of the company's stock worth $1,294,000 after acquiring an additional 3,064 shares during the period. DRW Securities LLC purchased a new stake in shares of AbbVie during the fourth quarter valued at approximately $798,000. F M Investments LLC grew its holdings in AbbVie by 13.9% during the 4th quarter. F M Investments LLC now owns 59,371 shares of the company's stock valued at $10,550,000 after purchasing an additional 7,226 shares in the last quarter. Finally, Redwood Park Advisors LLC purchased a new stake in shares of AbbVie during the fourth quarter worth about $40,000. 70.23% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several brokerages have issued reports on ABBV. Cantor Fitzgerald began coverage on AbbVie in a research note on Tuesday, April 22nd. They set an "overweight" rating and a $210.00 price objective on the stock. Citigroup upped their price target on AbbVie to $205.00 and gave the company a "hold" rating in a research report on Wednesday, June 11th. Raymond James Financial lifted their price objective on shares of AbbVie from $227.00 to $236.00 and gave the stock an "outperform" rating in a report on Friday, August 1st. Evercore ISI boosted their target price on shares of AbbVie from $204.00 to $205.00 and gave the company an "outperform" rating in a research note on Monday, April 28th. Finally, BNP Paribas upgraded shares of AbbVie to a "hold" rating in a research report on Thursday, May 8th. Seven investment analysts have rated the stock with a hold rating, eighteen have issued a buy rating and three have assigned a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $214.43.

• 3 Biotech Giants Gaining From U.S. Sales and Policy Shifts

View Our Latest Research Report on AbbVie

Insider Transactions at AbbVie

In related news, EVP Nicholas Donoghoe sold 13,295 shares of AbbVie stock in a transaction that occurred on Tuesday, August 5th. The stock was sold at an average price of $198.51, for a total value of $2,639,190.45. Following the sale, the executive vice president owned 58,247 shares of the company's stock, valued at approximately $11,562,611.97. This trade represents a 18.58% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 0.25% of the company's stock.

AbbVie Trading Up 1.3%

• If You Wanted To Buy AbbVie and Didn’t, There’s Still Time To Buy

ABBV stock opened at $198.77 on Friday. The business has a fifty day moving average price of $189.13 and a 200 day moving average price of $190.69. The company has a debt-to-equity ratio of 44.14, a current ratio of 0.74 and a quick ratio of 0.64. AbbVie Inc. has a fifty-two week low of $163.81 and a fifty-two week high of $218.66. The stock has a market capitalization of $351.13 billion, a price-to-earnings ratio of 94.65, a P/E/G ratio of 1.26 and a beta of 0.50.

AbbVie (NYSE:ABBV - Get Free Report) last posted its quarterly earnings results on Thursday, July 31st. The company reported $2.97 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.24 by ($0.27). The firm had revenue of $15.42 billion during the quarter, compared to the consensus estimate of $14.93 billion. AbbVie had a net margin of 6.45% and a return on equity of 699.66%. AbbVie's revenue was up 6.6% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.65 EPS. Analysts expect that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, August 15th. Investors of record on Tuesday, July 15th will be paid a dividend of $1.64 per share. This represents a $6.56 dividend on an annualized basis and a yield of 3.3%. The ex-dividend date of this dividend is Tuesday, July 15th. AbbVie's dividend payout ratio is presently 312.38%.

AbbVie Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.

See Also

• Five stocks we like better than AbbVie
• Insider Trades May Not Tell You What You Think
• 3 AI Infrastructure Stocks Powering the Next Tech Revolution
• 3 Warren Buffett Stocks to Buy Now
• Why Monolithic Power's Earnings and Guidance Ignited a Rally
• Ride Out The Recession With These Dividend Kings
• AppLovin’s Q2 Miss Spooks Market, But Wall Street Doubles Down

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in AbbVie Right Now?

Before you consider AbbVie, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbbVie wasn't on the list.

While AbbVie currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here